<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Moore MN</submitter><funding>NIDA NIH HHS</funding><pagination>229-238</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12675282</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>648(8092)</volume><pubmed_abstract>G-protein-coupled receptors (GPCRs) convert extracellular signals into intracellular responses by signalling through 16 subtypes of Gα proteins and two β-arrestin proteins. Biased compounds-molecules that preferentially activate a subset of these proteins-engage therapy-relevant pathways more selectively&lt;sup>1&lt;/sup> and promise to be safer, more effective medications than compounds that uniformly activate all pathways&lt;sup>2&lt;/sup>. However, the determinants of bias are poorly understood, and we lack rationally designed molecules that select for specific G proteins. Here, using the prototypical class A GPCR neurotensin receptor 1 (NTSR1), we show that small molecules that bind to the intracellular GPCR-transducer interface change G protein coupling by subtype-specific and predictable mechani</pubmed_abstract><journal>Nature</journal><pubmed_title>Designing allosteric modulators to change GPCR G protein subtype selectivity.</pubmed_title><pmcid>PMC12675282</pmcid><funding_grant_id>R01 DA061773</funding_grant_id><funding_grant_id>UH3 DA050316</funding_grant_id><funding_grant_id>R00 DA048970</funding_grant_id><funding_grant_id>P30 DA048742</funding_grant_id><funding_grant_id>F31 DA062411</funding_grant_id><pubmed_authors>Person KL</pubmed_authors><pubmed_authors>Robleto VL</pubmed_authors><pubmed_authors>Olson SH</pubmed_authors><pubmed_authors>Moore MN</pubmed_authors><pubmed_authors>Slosky LM</pubmed_authors><pubmed_authors>Foster N</pubmed_authors><pubmed_authors>Barak LS</pubmed_authors><pubmed_authors>Krusemark CL</pubmed_authors><pubmed_authors>Jackson MR</pubmed_authors><pubmed_authors>Inoue A</pubmed_authors><pubmed_authors>Marron Fernandez de Velasco E</pubmed_authors><pubmed_authors>Alwin AR</pubmed_authors><pubmed_authors>Sheedlo MJ</pubmed_authors><pubmed_authors>Ray C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Designing allosteric modulators to change GPCR G protein subtype selectivity.</name><description>G-protein-coupled receptors (GPCRs) convert extracellular signals into intracellular responses by signalling through 16 subtypes of Gα proteins and two β-arrestin proteins. Biased compounds-molecules that preferentially activate a subset of these proteins-engage therapy-relevant pathways more selectively&lt;sup>1&lt;/sup> and promise to be safer, more effective medications than compounds that uniformly activate all pathways&lt;sup>2&lt;/sup>. However, the determinants of bias are poorly understood, and we lack rationally designed molecules that select for specific G proteins. Here, using the prototypical class A GPCR neurotensin receptor 1 (NTSR1), we show that small molecules that bind to the intracellular GPCR-transducer interface change G protein coupling by subtype-specific and predictable mechani</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-07-15T13:51:41.323Z</modification><creation>2026-07-05T03:11:28.93Z</creation></dates><accession>S-EPMC12675282</accession><cross_references><pubmed>41125894</pubmed><doi>10.1038/s41586-025-09643-2</doi></cross_references></HashMap>